UB Paderborn / Katalog / Suche / in CDI

1 – 17 von 17

Sortiert nach

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Molecular cancer therapeutics, 2016-11, Vol.15 (11), p.2563-2574

2016

Link zum Volltext

Verfügbarkeit prüfen

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Clinical cancer research, 2007-03, Vol.13 (5), p.1576-1583

2007

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

British journal of cancer, 2021-01, Vol.124 (2), p.383-390

2021

Link zum Volltext

Verfügbarkeit prüfen

Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

Clinical cancer research, 2017-02, Vol.23 (4), p.1025-1035

2017

Link zum Volltext

Verfügbarkeit prüfen

A Dual Role for the Kinase-Like Domain of the Tyrosine Kinase Tyk2 in Interferon-α Signaling

Proceedings of the National Academy of Sciences - PNAS, 2000-08, Vol.97 (16), p.8991-8996

2000

Link zum Volltext

Verfügbarkeit prüfen

Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones

Journal of medicinal chemistry, 2006-01, Vol.49 (2), p.441-444

2006

Link zum Volltext

Verfügbarkeit prüfen

Characterization and Cloning of a 58/53-kDa Substrate of the Insulin Receptor Tyrosine Kinase (∗)

The Journal of biological chemistry, 1996-02, Vol.271 (6), p.2921-2928

1996

Link zum Volltext

Verfügbarkeit prüfen

Abstract B55: Exploratory biomarker analyses of tumor and peripheral blood samples from the phase I durvalumab plus gefitinib trial in EGFR-mutated NSCLC

Cancer immunology research, 2020-03, Vol.8 (3_Supplement), p.B55-B55

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1677: Preclinical activity of Vintafolide/MK-8109 monotherapy and in combination with standard of care therapy in triple-negative breast cancer models

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1677-1677

2014

Link zum Volltext

Verfügbarkeit prüfen

Insulin receptor signaling in Madin-Darby canine kidney cells overexpressing the human insulin receptor

Diabetes (New York, N.Y.), 1994-11, Vol.43 (11), p.1297

1994

Link zum Volltext

Verfügbarkeit prüfen

Disruption of a putative SH3 domain and the proline-rich motifs in the 53-kDa substrate of the insulin receptor kinase does not alter its subcellular localization or ability to serve as a substrate

Journal of cellular biochemistry, 1998-02, Vol.68 (2), p.139-150

1998

Link zum Volltext

Verfügbarkeit prüfen

Evolution of Rodent Lysozymes: Isolation and Sequence of the Rat Lysozyme Genes

Molecular phylogenetics and evolution, 1993-03, Vol.2 (1), p.65-75

1993

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK

Cancer, 2006, p.83-132

2006

Link zum Volltext

Verfügbarkeit prüfen

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

Oncogene, 2003-08, Vol.22 (32), p.4953-4963

2003

Link zum Volltext

Verfügbarkeit prüfen

Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3047-3047

2015

Link zum Volltext

Verfügbarkeit prüfen

Association of Perceived Stress and Discrimination on Medication Adherence among Diverse Patients with Uncontrolled Hypertension

Ethnicity & disease, 2021, Vol.31 (1), p.97-108

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 17 von 17

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(16)
Buchkapitel
(1)

Sprache

Englisch
(17)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

Discovery of MK-4688: an Efficient Inhibitor of the HDM2–p53 Protein–Protein Interaction

Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

A Dual Role for the Kinase-Like Domain of the Tyrosine Kinase Tyk2 in Interferon-α Signaling

Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones

Characterization and Cloning of a 58/53-kDa Substrate of the Insulin Receptor Tyrosine Kinase (∗)

Abstract B55: Exploratory biomarker analyses of tumor and peripheral blood samples from the phase I durvalumab plus gefitinib trial in EGFR-mutated NSCLC

Abstract 1677: Preclinical activity of Vintafolide/MK-8109 monotherapy and in combination with standard of care therapy in triple-negative breast cancer models

Insulin receptor signaling in Madin-Darby canine kidney cells overexpressing the human insulin receptor

Disruption of a putative SH3 domain and the proline-rich motifs in the 53-kDa substrate of the insulin receptor kinase does not alter its subcellular localization or ability to serve as a substrate

Evolution of Rodent Lysozymes: Isolation and Sequence of the Rat Lysozyme Genes

Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC)

Association of Perceived Stress and Discrimination on Medication Adherence among Diverse Patients with Uncontrolled Hypertension

Suchergebnisse filtern